BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ali YM, Kuriya B, Orozco C, Cush JJ, Keystone EC. Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 2010;37:9-17. [PMID: 20008917 DOI: 10.3899/jrheum.090563] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Viktil K, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150 000 pregnant women and expectant fathers. Scandinavian Journal of Rheumatology 2012;41:196-201. [DOI: 10.3109/03009742.2011.626442] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
2 Rademaker M, Agnew K, Andrews M, Armour K, Baker C, Foley P, Frew J, Gebauer K, Gupta M, Kennedy D, Marshman G, Sullivan J. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol 2018;59:86-100. [PMID: 28543445 DOI: 10.1111/ajd.12641] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
3 Freymond N, Cottin V, Cordier JF. Infiltrative lung diseases in pregnancy. Clin Chest Med 2011;32:133-46. [PMID: 21277455 DOI: 10.1016/j.ccm.2010.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Clowse ME, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Mahadevan U. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. J Rheumatol 2015;42:2270-8. [DOI: 10.3899/jrheum.140189] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 8.5] [Reference Citation Analysis]
5 Owczarek W, Walecka I, Lesiak A, Czajkowski R, Reich A, Zerda I, Narbutt J. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. Postepy Dermatol Alergol 2020;37:821-30. [PMID: 33603597 DOI: 10.5114/ada.2020.102089] [Reference Citation Analysis]
6 Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, Nesbitt A. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol 2016;116:7-12. [PMID: 27123565 DOI: 10.1016/j.jri.2016.04.284] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
7 Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol 2011;7:639-52. [DOI: 10.1038/nrrheum.2011.145] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
8 Yiu ZZ, Griffiths CE, Warren RB. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol. 2014;171:485-491. [PMID: 24749725 DOI: 10.1111/bjd.13060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
9 Hazes JM, Coulie PG, Geenen V, Vermeire S, Carbonnel F, Louis E, Masson P, De Keyser F. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford). 2011;50:1955-1968. [PMID: 21890617 DOI: 10.1093/rheumatology/ker302] [Cited by in Crossref: 80] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
10 Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377-1385. [PMID: 24352337 DOI: 10.1093/rheumatology/ket409] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
11 Gogia M, Furst DE. Rheumatoid arthritis and pregnancy: Disease activity, pregnancy outcomes, and treatment options during pregnancy and lactation. Drug Dev Res 2011;72:689-702. [DOI: 10.1002/ddr.20478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Ruiz V, Manubens E, Puig L. Psoriasis y embarazo: revisión (i). Actas Dermo-Sifiliográficas 2014;105:734-43. [DOI: 10.1016/j.ad.2013.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
13 Märker-Hermann E, Fischer-Betz R. Rheumatic diseases and pregnancy. Curr Opin Obstet Gynecol 2010;22:458-65. [PMID: 20966752 DOI: 10.1097/GCO.0b013e3283404d67] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
14 Ferreira C, Azevedo A, Nogueira M, Torres T. Management of psoriasis in pregnancy - a review of the evidence to date. Drugs Context 2020;9:2019-11-6. [PMID: 32201494 DOI: 10.7573/dic.2019-11-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
15 Lis K, Kuzawińska O, Bałkowiec-Iskra E. Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci 2014;10:1175-85. [PMID: 25624856 DOI: 10.5114/aoms.2014.47827] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 14.5] [Reference Citation Analysis]
16 Hornbeak DM, Thorne JE. Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention. Taiwan J Ophthalmol 2015;5:156-63. [PMID: 29018691 DOI: 10.1016/j.tjo.2015.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
17 Calleja-Agius J, Muttukrishna S, Pizzey AR, Jauniaux E. Pro- and antiinflammatory cytokines in threatened miscarriages. Am J Obstet Gynecol 2011;205:83.e8-16. [PMID: 21514552 DOI: 10.1016/j.ajog.2011.02.051] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
18 Fischer-Betz RE, Schneider M. [Biologics during pregnancy and breast--feeding]. Z Rheumatol 2010;69:780-7. [PMID: 21063826 DOI: 10.1007/s00393-010-0640-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
19 Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (II). Actas Dermosifiliogr 2014;105:813-21. [PMID: 24314892 DOI: 10.1016/j.ad.2013.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78 Suppl 1:15-185. [PMID: 21703545 DOI: 10.1016/S1297-319X(11)70001-X] [Cited by in Crossref: 53] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
21 Elliott AB, Chakravarty EF. Immunosuppressive Medications during Pregnancy and Lactation in Women with Autoimmune Diseases. Womens Health (Lond Engl) 2010;6:431-42. [DOI: 10.2217/whe.10.24] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]